East Sussex - Better Together
NHS

6.6.2 Bisphosphonates and other drugs affecting bone metabolism

MHRA Safety Update: Bisphosphonates: atypical femoral fractures

MHRA Safety Update: Bisphosphonates: osteonecrosis of the jaw

MHRA Safety Update: Bisphosphonates: atrial fibrillation

For guidance on drug treatment of osteoporosis see primary and secondary prevention pathways

NICE NG101: Early and locally advanced breast cancer: diagnosis and management

For daily dosing

Pack
28 tablet

For weekly dosing

Pack
4 tablet

Daily dose

Pack
28 tablet

Daily dose for Paget's disease of bone

Pack
28 tablet

Weekly dose

Pack
4 tablet

Adjuvant treatment in post-menopausal women with breast cancer at high risk of recurrence. For use in accordance with NICE NG101 where zoledronate infusion is declined due to patient preference or side effects.

Pack
60 tablet

These products should only be administered by staff trained to administer intravenous infusions in a hospital or specialist centre

For cancer indications only

For first line adjuvant treatment in post-menopausal women with breast cancer at high risk of recurrence in accordance with NICE NG101

Pack
1 vial

For osteoporosis only

Pack
1 bottle
  • First Line Drugs
  • Second Line Drugs
  • Specialist Initiated Drugs
  • Specialist Only Drugs
  • Mixed Status